Fibronol: New Supplement Improves Sleep and Delivers Energy

For millions of fibromyalgia (FMS) patients, there are very few effective therapies available to treat the multitude of symptoms they are enduring. The quality of life for many patients is severely compromised by the primary symptoms of FMS (chronic sleep disorders, fatigue, and pain) and further complicated by a variety of secondary symptoms (including IBS, headaches, “fibro-fog”, and depression).

The specific origins of FMS are not fully understood, however knowledge of this disease’s symptoms and mechanisms is increasing. Many FMS patients have suppressed levels of Human Growth Hormone (HGH), which is a critical enzyme supporting the body’s ability to grow or rebuild tissue and achieve deep, sound sleep. FMS patients also often have low levels of serotonin, an important neurotransmitter that promotes longer and sounder sleep, higher energy levels, and can moderate or decrease pain sensations. Both of these conditions arise from sleep disorders that interrupt or prevent deep, restorative sleep.

The perception of pain experienced by FMS patients is significantly compounded by the presence of “nociception”, where sensitivity to pain is amplified substantially compared to those not suffering from fibromyalgia. Nociception is likely a result of elevated levels of Substance P – a neurotransmitter of pain impulses – that is often present in FMS patients. Higher levels of Substance P can arise from the suppression of HGH production.

The efficacy of current treatments for FMS is limited in part by there not being any FDA-approved medications for fibromyalgia. Frequently, a variety of off-label prescribed medications are combined with other therapies (naturopathic, exercise, massage) to achieve improvement in FMS symptoms and provide the patient with some ability to lead a more normal life. However, each therapy often delivers only limited relief, so that small incremental gains rather than significant improvements in symptom relief have too often become the expectation of new treatments.

The limited efficacy of existing treatments in managing FMS symptoms is a testament to the continuing large, unmet medical needs of the FMS patient population. However recent clinical trials have shown that there is a new safe, effective, and natural supplement available that addresses many of these needs of FMS patients. Fibronol® http://www.fibronol.com/fibronol.html is a nutraceutical product that delivered significant relief from many primary FMS symptoms in a recently completed clinical trial. Some of the key benefits experienced by clinical trial participants included:

- 1.6 hours of additional sleep per night, with sleep overall being deeper and less-interrupted (i.e. an 80% increase in sleep soundness);
- A 71% increase in energy accompanied by a 30% reduction in fatigue;
- 2.4 more “good” days per week;
- A 31% decrease in pain;



The clinical study was a double blind, placebo-controlled trial in 36 FMS patients (29 completions) over an 8-week period. The only adverse event noted in the clinical trial was Fibronol’s tendency to exacerbate some patient’s pre-existing IBS condition of diarrhea. No adverse drug-nutraceutical interactions were noted with Fibronol use. The statistical significance of all primary outcome measures was uniformly strong (p<.001, i.e. less than one chance in one thousand that similar results could occur by random chance alone). The statistical veracity of these results is generally higher than similar measures recently reported in advanced clinical studies on pharmaceutical developmental products.

Fibronol is classified as a natural food supplement. The primary ingredient (SEANOL-F) is a powerful polyphenol/phlorotannin extract from brown algae that has uniquely strong anti-inflammatory and anti-oxidant properties that combine to provide potent FMS symptom relief. Other Fibronol ingredients include magnesium to promote tissue repair and growth, aloe vera for its anti-inflammatory properties, along with malic acid and Vitamin B-1 to help maintain normal cellular function and increase levels of ATP, the cellular based energy source.

One of the more notable impacts of Fibronol was the significant improvement in the quality and length of sleep experienced by FMS patients. Benefits arising from improved sleep include increased levels of HGH and serotonin with corresponding reductions in Substance P levels. This is a primary explanation for the increases in energy, decreases in fatigue, increases in comfort, along with improved overall condition experienced by many (80%) of the clinical trial participants.

While Fibronol clearly does not represent a “cure” for FMS, it has been clinically proven to deliver significant improvement in FMS symptoms in its role as a safe and effective adjunct supplement complementing individual standards of care established by FMS patients with their physician. Considering the persuasiveness of the clinical results, Fibronol has the potential to significantly improve the quality of life for many FMS patients.

To learn more about Fibronol, the clinical trials, or review statements from clinical trial participants, please visit www.fibronol.com.